Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids
NCT06882772
Summary
Butyric acid has been shown to promote gut health and improve the microbiome in multiple adult studies. In preliminary studies in older children with inflammatory bowel disease, butyric acid was shown to be safe. However, it's suitability for infants and young children with congenital heart disease (CHD) has yet to be determined. This study will examine butyric acid supplementation in infants and children, ages 1 month to 3 years, with CHD who require cardiac surgery with cardiopulmonary bypass. Study goals include determining the safety and tolerability of butyric acid supplementation before cardiac surgery, and to identify changes in gut microbial communities, metabolic profile, and genetic markers intestinal function. Also, the study seeks to establish a reduction in inflammation (inflammatory signaling) after cardiopulmonary bypass (CPB) in participants receiving butyric acid.
Eligibility
Inclusion Criteria: * Infants and Children undergoing cardiac surgery with cardiopulmonary bypass Exclusion Criteria: * Antibiotics, surgery, or chemotherapy within the past 8 weeks * Continuous enteral feeds before surgery * GI pathology or intestinal surgery (excluding G-tube) * Liver disease with elevated transaminitis or dialysis-dependent renal disease
Conditions2
Interventions2
Locations1 site
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06882772